View on Pubmed.gov 40703266 | View on doi.org 10.3389/fmed.20...
The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report.
- Medical Oncology Department, Catalan Institute of Oncology, Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain.
- OncoGIR-PRO (Precision Oncology Group), Girona Biomedical Research Institute (IDIBGI-CERCA), Girona, Catalonia, Spain.
- Medical Science Department, School of Medicine, University of Girona, Girona, Catalonia, Spain.
- Medical Oncology Department, Catalan Institute of Oncology, Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain. OncoGIR-PRO (Precision Oncology Group), Girona Biomedical Research Institute (IDIBGI-CERCA), Girona, Catalonia, Spain.
- Medical Science Department, School of Medicine, University of Girona, Girona, Catalonia, Spain. Department of Pathology, Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain.
- Molecular Diagnostics and Precision Medicine Unit, Girona Territorial Clinical Laboratory, Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain.
- Department of Pathology, Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain.
- Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Girona, Catalonia, Spain.
- Metabolism & Cancer Group, Girona Biomedical Research Institute (IDIBGI), Girona, Catalonia, Spain.
- Department of Radiology, Diagnostic Imaging Institute, Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain.
- Department of Radiotherapy, Catalan Institute of Oncology, Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain.
Abstract
Background
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with brain metastases (BM), which are associated with poor prognosis. Pembrolizumab has shown promising results in advanced NSCLC with PD-L1 ≥ 50%, including patients with BM. Silibinin is a flavonolignan with known blood-brain barrier permeability and anti-BM activity associated with inhibition of the STAT3/TIMP1 signaling axis. To the best of our knowledge, this is the first clinical evidence of combining silibinin with pembrolizumab to achieve a durable partial response in BM, lasting over 9 months.
Case Report
We present the case of a 72-year-old male with stage IVB lung adenocarcinoma and BM, who achieved durable intracranial tumor control with a combination of pembrolizumab and silibinin supplementation. Initial treatment with brain hypofractionated stereotactic radiotherapy and pembrolizumab led to a 14-month partial response. Progression occurred with a new jejunal metastasis and increasing temporal brain lesion. After declining whole-brain radiotherapy, the patient continued pembrolizumab with silibinin (630 mg/day), on a compassionate basis. At 2 months, a partial response in the temporal lobe lesion was observed, and at 9 months, nearly complete intracranial response was achieved with no extracranial progression. Molecular analysis revealed high PD-L1 expression and a METex14, potentially enhancing the response to immunotherapy.
Conclusion
This case highlights the potential of silibinin as an adjuvant therapy to enhance anti-PD-1 efficacy in brain metastases, possibly by targeting STAT3/TIMP1-driven immunosuppressive astrocytes. Further investigation of the role of silibinin in improving immunotherapy outcomes in advanced lung cancer patients with BM is required.
References
Cancer Med. 2023 Jun;12(11):12438-12451
Cells. 2021 Jun 29;10(7):
Ann Oncol. 2024 Jul;35(7):588-606
Eur J Cancer. 2024 Mar;199:113556
Conflict of interest statement
ET-V has received support for attendance at meetings and/or travel from Lilly, Roche, and MSD. AH-M has received meeting attendance support from BMS and Lilly. JB-B reports personal honoraria from MSD, BMS, AstraZeneca, and Sanofi, outside the submitted work and has received support for attending meetings and/or travel from Takeda, MSD, and Roche. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
Copyright
Copyright © 2025 Bosch-Barrera, Sais, Teixidor-Vilà, Vásquez-Dongo, Hernandez-Martínez, Romera, Pinsach-Abuin, del Olmo, Oliveras, Polonio-Alcalá, Verdura, Soriano-Gamero, Pineda, Rosales and Menendez.